false
0001541157
0001541157
2026-10-28
2026-10-28
0001541157
AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember
2026-10-28
2026-10-28
0001541157
AKTX:OrdinarySharesParValue0.000000005PerShareMember
2026-10-28
2026-10-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 28, 2026
Akari
Therapeutics, Plc
(Exact
Name of Registrant as Specified in Charter)
| England
and Wales |
|
001-36288 |
|
98-1034922 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
401
East Jackson Street, Suite 3300
Tampa,
FL 33602
(Address,
including zip code, of Principal Executive Offices)
Registrant’s
telephone number, including area code: (929) 274-7510
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class: |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| American
Depositary Shares, each representing 80,000 Ordinary Shares |
|
AKTX |
|
The Nasdaq Capital Market |
| Ordinary
Shares, par value $0.000000005 per share* |
|
|
|
|
*Trading,
but only in connection with the American Depositary Shares.
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
October 28, 2026, Akari Therapeutics, Plc (the “Company”) held a General Meeting (the “Special General Meeting”).
Proxies were solicited pursuant to the Company’s Proxy Statement, filed with the Securities and Exchange Commission under
Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of ordinary shares entitled to vote at the Special General
Meeting was 186,091,889,533. The number of ordinary shares present or represented by valid proxy at the Special General Meeting established
a quorum for the Special General Meeting. The Special General Meeting duly proceeded in accordance with the provisions of the articles
of association of the Company.
The
voting results below are final and reported in ordinary shares.
| Ordinary Resolution | |
For | | |
Against | | |
Abstain | |
| To generally and unconditionally authorize an increase in the number of shares available for the grant of awards under the 2023 Plan by 144,000,000,000 ordinary shares (the equivalent of 1,800,000 American Depositary Shares (“ADSs”)) from 19,806,000,000 ordinary shares to an aggregate of 163,806,000,000 ordinary shares (the equivalent of 2,047,575 ADSs) under the 2023 Plan plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Plan, to the extent such awards are forfeited or cancelled, or expire unexercised. | |
| 79,142,490,228 | | |
| 1,314,720,000 | | |
| 22,005,228 | |
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| |
|
|
| 104 |
|
The
cover page from this Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Akari
Therapeutics, Plc |
| |
|
| Date:
October 30, 2026 |
By: |
/s/
Abizer Gaslightwala |
| |
|
Abizer
Gaslightwala |
| |
|
President
and Chief Executive Officer |
